Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Annunziata Website

Christina M. Annunziata, M.D., Ph.D.

Selected Publications

1)  House CD, Hernandez L, Annunziata CM.
Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer.
Front Oncol. 4: 26, 2014.
[Journal]
2)  Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.
A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.
Mol Clin Oncol. 1: 565-569, 2013.
[Journal]
3)  Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Br. J. Cancer. 109: 1072-8, 2013.
[Journal]
4)  Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.
Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.
Cancer. 119: 1357-64, 2013.
[Journal]
5)  Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O.
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Am. J. Hematol. 88: 89-92, 2013.
[Journal]
6)  Annunziata CM, Kohn EC.
Novel facts about FAK: new connections to drug resistance?.
J. Natl. Cancer Inst. 105: 1430-1, 2013.
[Journal]
7)  Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC.
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Mol. Cell Proteomics. 12: 1621-31, 2013.
[Journal]
8)  Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC.
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.
Cancer. 118: 1543-53, 2012.
[Journal]
9)  Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J.
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 109: E3659-67, 2012.
[Journal]
10)  Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M, Davidson B, Annunziata CM.
IKK-e coordinates invasion and metastasis of ovarian cancer.
Cancer Res. 72: 5494-504, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/21/2014.